Synaptic Vesicle Protein 2A
| Synaptic Vesicle Glycoprotein 2A | ||
|---|---|---|
| Properties of human protein | ||
| Mass / length primary structure | 82.7 kilodaltons / 742 amino acids (isoform 1)
76.6 kilodaltons / 682 amino acids (isoform 2) |
|
| Isoforms | 2 | |
| Identifier | ||
| Gene names | SV2A SV2; KIAA0736 | |
| External IDs | ||
| Orthologue | ||
| human | House mouse | |
| Entrez | 9900 | 64051 |
| Ensemble | ENSG00000159164 | ENSMUSG00000038486 |
| UniProt | Q7L0J3 | Q9JIS5 |
| Refseq (mRNA) | NM_001278719 | NM_022030 |
| Refseq (protein) | NP_001265648 | NP_071313 |
| Gene locus | Chr 1: 149.9 - 149.92 Mb | Chr 3: 96.18 - 96.2 Mb |
| PubMed search | 9900 |
64051
|
The synaptic vesicle protein 2A ( English Synaptic vesicle glycoprotein 2A , abk. SV2A ) is a vesicle protein of the SV2 protein family that occurs ubiquitously in the brain and is encoded in the human genome on the SV2A gene . The protein is the target of the anticonvulsants levetiracetam and brivaracetam .
function
SV2A is involved in neural stimulus transmission. The exact molecular mechanism of action is not known, but it is assumed that the vesicle protein 2A makes vesicles fusible so that they fuse with the presynaptic membrane and release their messenger substances into the synaptic cleft .
Web links
- Dissertation by Jan Kellner: Association study on genetic variants of SV2C and attention deficit / hyperactivity disorder PDF; 862 kB
- Dissertation by Daniela Manthey: The neurotoxicity of the antiepileptic drugs Levetiracetam and Sultiam in the immature brain of the rat PDF; 1.2 MB
- Diploma thesis by Miguel Barrera PDF; 3.01 MB